H3.Investigation summary: the complaint investigation for discrepant results when using the bd max¿ enteric bacterial panel assay (ref.442963) from lots 3081374 was performed by the review of the manufacturing records, review of customer¿s data and by the complaint¿s history review.Review of the manufacturing records of bd max¿ enteric bacterial panel assay indicated that lot 3081374 was manufactured according to specifications and met performance requirements.Customer complained about salmonella positive results on two patient samples which were later negative in culture and in the repeat test.Customer provided databases from instruments ct2207 and ct1211 for investigation.Additional information revealed that runs 519 and 524 from ct2207 and 2578 from ct1211 are the specific runs involved in the issue.Manual pcr curve adjudication of the salmonella positive samples (run 519, positions a2 and a3) revealed late and low, but true amplification, without anomaly indicative of true low positive results.After the initial run, new sample buffer tubes were prepared and tested in runs 524 and 2578 and gave salmonella negative results.Curves analysis of the repeat tests did not show any anomaly, suggesting true negative results.Low positive samples such as those obtained in the initial test can occur due to concentration in the specimen being at or near the limit of detection of the assay or through environmental or cross contamination introduced during the sample preparation at the customer¿s site.Moreover, limit of detection can vary between different assays.Nevertheless, manual curve adjudication has limitations; visual examination of pcr curves for low signal is a conservative assessment of the data.Bd was unable to identify the exact cause of the customer¿s discrepant results.Nonetheless, no reagents issue is suspected.The root cause was not identified.There is no indication of a reagent issue based on the analysis of the complaints received for discrepant results on the bd max¿ enteric bacterial panel assay lot 3081374.Bd cannot confirm the complaint based on the investigation that was performed.Bd did not initiate a corrective and preventive action (capa) since no new hazard was identified.Bd quality will continue to monitor for trends.
|